Select a Region North America


Chris Quesenberry

Chief Commercial Officer


Commercialization, Launch Readiness, Leadership, Management, Marketing and Advertising, Rare Disease, Sales, Stakeholder Engagement & Promotion (Patients, Payers, Providers), Training

Chris leads the EVERSANA and Evoke partnership in the launch and commercialization of GIMOTI®, a treatment for adult patients with diabetic gastroparesis. He brings more than 30 years of experience in building and executing on commercial strategies for pharmaceutical companies and has held roles across commercial strategy sales, marketing and operations. He has spent most of his career in executive-level roles at leading pharmaceutical and life sciences companies. In his current role, he leads the commercialization efforts for GIMOTI®, which include driving strategic decision-making and execution across marketing, sales, market access and commercial operations, among other responsibilities.

Chris holds a bachelor’s degree in biology from Virginia Tech.

Articles by Chris Quesenberry

Trade & Channel Strategies: Partnership Pavilion Panel

Panel Summary: The challenges of commercialization are abundant. Now more than ever, the right partner and understanding the patient journey are pivotal to commercialization success and ensuring patient access to therapy. During this panel, EVERSANA, EVOKE and UpScriptHealth experts discuss the launch and later pivot in strategy of a novel therapy. Speed to therapy initiation is crucial for patients of this indication to avoid isolation due to symptoms; however, diagnosis takes an average of 5 years and 5+ providers. There is also difficulty often associated with Rx approval. EVOKE had four full-time employees that spent 15 years working towards obtaining therapy approval but did not participate in pre-commercialization activities due […]

Interested in scheduling a meeting or speaking event?


  • このフィールドは入力チェック用です。変更しないでください。